BR112017000978A2 - mioinositol e probióticos e usos - Google Patents
mioinositol e probióticos e usosInfo
- Publication number
- BR112017000978A2 BR112017000978A2 BR112017000978A BR112017000978A BR112017000978A2 BR 112017000978 A2 BR112017000978 A2 BR 112017000978A2 BR 112017000978 A BR112017000978 A BR 112017000978A BR 112017000978 A BR112017000978 A BR 112017000978A BR 112017000978 A2 BR112017000978 A2 BR 112017000978A2
- Authority
- BR
- Brazil
- Prior art keywords
- myoinositol
- probiotics
- insulin sensitivity
- prevent
- diabetes
- Prior art date
Links
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 title abstract 2
- 229960000367 inositol Drugs 0.000 title abstract 2
- 239000006041 probiotic Substances 0.000 title abstract 2
- 235000018291 probiotics Nutrition 0.000 title abstract 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 title abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 abstract 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Botany (AREA)
- Pediatric Medicine (AREA)
Abstract
a presente invenção refere-se ao mioinositol e a um ou mais probióticos para uso para melhorar a sensibilidade à insulina e/ou tratar ou prevenir diabetes tipo ii e/ou prevenir cvd e/ou uma condição associada a uma baixa sensibilidade à insulina e/ou qualquer um dos anteriores em um indivíduo.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14180399 | 2014-08-08 | ||
EP14180403 | 2014-08-08 | ||
EP15170902 | 2015-06-05 | ||
PCT/EP2015/068187 WO2016020488A1 (en) | 2014-08-08 | 2015-08-06 | Myo-inositol and probiotics and uses |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017000978A2 true BR112017000978A2 (pt) | 2017-11-21 |
Family
ID=53836568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017000978A BR112017000978A2 (pt) | 2014-08-08 | 2015-08-06 | mioinositol e probióticos e usos |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3177277B1 (pt) |
CN (1) | CN106794204A (pt) |
BR (1) | BR112017000978A2 (pt) |
CA (1) | CA2952763C (pt) |
ES (1) | ES2792865T3 (pt) |
MX (1) | MX2017001734A (pt) |
PH (1) | PH12017500052A1 (pt) |
WO (1) | WO2016020488A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180129944A (ko) * | 2016-04-14 | 2018-12-05 | 듀폰 뉴트리션 바이오사이언시즈 에이피에스 | 식품, 에너지 및/또는 지방 섭취 감소를 위한 비피더스균 |
BR112018070512A2 (pt) * | 2016-04-14 | 2019-01-29 | Dupont Nutrition Biosci Aps | composição, usos de uma composição e método para aumentar a massa corporal magra |
KR101938865B1 (ko) * | 2016-11-03 | 2019-01-16 | 주식회사 쎌바이오텍 | 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
KR20180049731A (ko) * | 2016-11-03 | 2018-05-11 | 주식회사 쎌바이오텍 | 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
US11898184B2 (en) | 2017-09-07 | 2024-02-13 | Sweet Sense Inc. | Low glycemic sugar composition |
EP3704958A4 (en) * | 2017-10-31 | 2021-06-30 | Morinaga Milk Industry Co., Ltd. | COMPOSITION FOR INCREASING MUSCLE MASS |
CN108813262A (zh) * | 2018-07-02 | 2018-11-16 | 杭州相生相成科技有限公司 | 一种含dha藻油的复合益生菌固体饮料 |
JP2022546267A (ja) * | 2019-08-30 | 2022-11-04 | ソシエテ・デ・プロデュイ・ネスレ・エス・アー | scyllo-イノシトール及びβ細胞介在性疾患 |
EP4034092A1 (en) * | 2019-09-24 | 2022-08-03 | Société des Produits Nestlé S.A. | Scyllo-inositol and its use as insulin sensitizer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW282398B (pt) * | 1993-12-22 | 1996-08-01 | Bristol Myers Squibb Co | |
CN1123113A (zh) * | 1994-11-18 | 1996-05-29 | 郭湘泗 | 用于特效减肥的超浓缩营养素 |
ITRM20040505A1 (it) * | 2004-10-15 | 2005-01-15 | Cd Invest | Liofilizzati di batteri lattici e bifidobatteri ad alta dispersibilita'. |
US20060088574A1 (en) * | 2004-10-25 | 2006-04-27 | Manning Paul B | Nutritional supplements |
JP2006213684A (ja) * | 2005-02-07 | 2006-08-17 | Hokko Chem Ind Co Ltd | インスリン抵抗性改善に用いられる組成物及び健康用食品 |
SE529185C2 (sv) * | 2005-10-07 | 2007-05-22 | Arla Foods Amba | Användning av probiotiska bakterier för tillverkning av livsmedel eller läkemedel för förhindrande av övervikt |
EP1974734A1 (en) * | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
EP2011506A1 (en) * | 2007-07-05 | 2009-01-07 | Nestec S.A. | Supplementation of maternal diet |
US20120027737A1 (en) * | 2009-03-25 | 2012-02-02 | Chr-Hansen A/S | Use of probiotics to ameliorate diet-induced insulin resistance |
EP2452573A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Age-tailored nutritional composition with animal fats and vegetable fats |
EP2452575A1 (en) * | 2010-11-15 | 2012-05-16 | Nestec S.A. | Array of age-tailored nutritional formula with probiotics |
ITFI20110252A1 (it) * | 2011-11-22 | 2013-05-23 | Lo Li Pharma Srl | Composizione farmaceutica comprendente myo-inositolo e d-chiro-inositolo. |
-
2015
- 2015-08-06 BR BR112017000978A patent/BR112017000978A2/pt not_active Application Discontinuation
- 2015-08-06 MX MX2017001734A patent/MX2017001734A/es unknown
- 2015-08-06 WO PCT/EP2015/068187 patent/WO2016020488A1/en active Application Filing
- 2015-08-06 CN CN201580042526.9A patent/CN106794204A/zh active Pending
- 2015-08-06 ES ES15750347T patent/ES2792865T3/es active Active
- 2015-08-06 EP EP15750347.5A patent/EP3177277B1/en active Active
- 2015-08-06 CA CA2952763A patent/CA2952763C/en active Active
-
2017
- 2017-01-09 PH PH12017500052A patent/PH12017500052A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2952763A1 (en) | 2016-02-11 |
PH12017500052A1 (en) | 2017-05-22 |
MX2017001734A (es) | 2017-04-27 |
CA2952763C (en) | 2023-02-28 |
WO2016020488A1 (en) | 2016-02-11 |
EP3177277B1 (en) | 2020-03-11 |
ES2792865T3 (es) | 2020-11-12 |
EP3177277A1 (en) | 2017-06-14 |
CN106794204A (zh) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017000978A2 (pt) | mioinositol e probióticos e usos | |
BR112017007543A2 (pt) | peptídeos com propriedades anti-inflamatórias | |
CL2018002012A1 (es) | Derivados de maitansinoide, conjugados de los mismos y métodos de uso. | |
MX2016015997A (es) | Preparacion y uso de beta-d-nicotinamida ribosido cristalina. | |
BR112016018455A2 (pt) | composto, ácido, medicamento, métodos para prevenir ou tratar obesidade e diabetes melito e para inibir uma enteropeptidase, e, uso de um composto. | |
BR112016006319A2 (pt) | inibidores de irak e usos dos mesmos | |
BR112016029465A2 (pt) | chapa de aço elétrica | |
BR112016025819A2 (pt) | vetores de vírus adeno-associados para o tratamento de doenças de depósito lisossômico | |
MA40998A (fr) | Thérapies contre une envenimation, ainsi que compositions, systèmes et kits pharmaceutiques associés | |
BR112018008103A2 (pt) | análogos de celastrol | |
EP3297566A4 (en) | BIOMARKER-CONTROLLED TARGETED MOLECULAR THERAPEUTIC COMBINATIONS BASED ON KNOWLEDGE REPRESENTATION PATH ANALYSIS | |
BR112016025627A2 (pt) | biomarcadores e combinações dos mesmos para diagnóstico de tuberculose | |
CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. | |
CL2015002180A1 (es) | Terapia de combinación para el tratamiento de neumonía nosocomial | |
EA201791454A1 (ru) | Лекарственные формы для трансдермального введения | |
CL2016002151A1 (es) | Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico | |
BR112018012313A2 (pt) | composições que compreendem 15-hepe e métodos para uso das mesmas | |
CL2016001210A1 (es) | Análogos de bicalutamida o (s)- bicalutamida como compuestos activadores de la exocitosis para su uso en el tratamiento de un desorden de acúmulo lisosomal o glucogenosis. | |
BR112017002354A2 (pt) | artigo absorvente extensível | |
BR112017021194A2 (pt) | compostos espirocíclicos | |
BR112017011168A2 (pt) | medicamentos para retardar a doença de parkinson | |
BR112017001061A2 (pt) | combinação de vitamina d e zinco e seu uso | |
BR112017015099A2 (pt) | tratamento de pacientes pediátricos portadores de diabetes mellitus tipo 2 com lixisenatida | |
CL2016001098A1 (es) | Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales | |
BR112017014416A2 (pt) | sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |